Skip Navigation

JNCI Monographs 2001 2001(29):26-30;
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Williams, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, D. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute Monographs, No. 29, 26-30, 2001
© 2001 Oxford University Press

Inflammatory Cytokines and Mucosal Injury

David A. Williams

Affiliations of authors: Howard Hughes Medical Institute, Indiana University School of Medicine, Section of Pediatric Hematology/Oncology, Herman B Wells Center for Pediatric Research, and Department of Pediatrics, Indiana University School of Medicine, Indianapolis.

Correspondence to:David A. Williams, M.D., Herman B Wells Center for Pediatric Research, 1044 West Walnut St., Rm. 402, Indianapolis, IN 46202 (e-mail: dwilliam{at}iupui.edu).

The cause of mucosal injury in inflammatory bowel disease (IBD) is not clear but likely involves infectious agents or other toxins followed by an abnormal immune response in genetically susceptible individuals. The inflammatory cytokines appear to play a key role in both the susceptibility of some individuals and the tissue damage that accompanies IBD. The generation of transgenic and gene-targeted (knockout) animals has provided invaluable information regarding the cytokines and cellular immune effectors that are important in IBD. Information from these and other preclinical animal models, such as those involving interleukin 11, has led to human trials testing novel therapies for IBD and other diseases in which inflammation of the gut mucosa is an important component. Thus, expression of inflammatory cytokines appears to be an important target for the development of novel therapies for IBD and other diseases in which intestinal mucosal damage occurs, such as mucositis and graft-versus-host disease. [J Natl Cancer Inst Monogr 2001;29:26–30]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
X. Sun, H. Yang, K. Nose, S. Nose, E. Q. Haxhija, H. Koga, Y. Feng, and D. H. Teitelbaum
Decline in intestinal mucosal IL-10 expression and decreased intestinal barrier function in a mouse model of total parenteral nutrition
Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G139 - G147.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.